

## Recruitment Update

Site Name	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Total
Alberta Children's Hospital	15	19	7	12	53
BC Children's Hospital	3	7	0	0	10
Beatrix Children's Hospital, UMCG	56	49	27	4	136
Children's Hospital, London Health Sciences Centre	8	4	3	3	18
Children's Hospital of Eastern Ontario (CHEO)	4	0	1	2	7
Emma Children's Hospital, AMC	48	53	7	6	114
Erasmus MC	1	3	5	2	11
Hospital for Sick Children	86	44	4	30	164
IWK Health Centre	19	12	2	3	36
Jim Pattison Children's Hospital (Saskatoon)	6	10	2	0	18
Montréal Children's Hospital (MUHC)	11	1	0	8	20
St. Maartenskliniek	9	3	0	0	12
Stollery Children's Hospital	2	1	0	0	3
McMaster Children's Hospital	1	0	0	0	1
Wilhelmina Children's Hospital	118	133	64	20	335
Radboud UMC, Amalia Kinderzkhs	0	3	0	1	4
<b>Grand Total</b>	<b>387</b>	<b>342</b>	<b>122</b>	<b>91</b>	<b>942</b>

**Cohort descriptions:** Cohort 1 – new JIA diagnosis; Cohort 2 – starting biologic therapy; Cohort 3 – stopping biologic therapy; Cohort 4 – extreme phenotype (genetic or refractory component)

## General Study Updates

Our UCAN team wishes everyone a happy (*and warm*) Spring. As we welcome the new season, we would also like to welcome some new study related items:

- SUCCEED-kids:** we are delighted to share the roll-out of our newly launched project titled, "Safety immUNogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases – Kids (SUCCEED-Kids)." This study is supported by the COVID-19 Immunity Task Force (CIFT) and Public Health Agency of Canada (PHAC), which aims to examine vaccine durability and safety in children affected by autoimmune diseases.
- We hope the results from SUCCEED-Kids will help bridge the knowledge gap in vaccines safety in this population and provide valuable information to policy and decision makers to shape future recommendations. **Thank you to all supporting sites!**
- Cohort 4 Family Members:** our study team is also introducing the inclusion of *family members* into UCAN enrollment. This will enable and support our study teams aim to complete a deep genomic analysis on families affected by JIA.



## HEcon Updates

Congratulations to the team on their recently published paper:

Currie GR, Pham T, Twilt M, Ijzerman MJ, Hull PJ, Kip MMA, Benseler S, Hazlewood GS, Yeung R, Wulffraat N, Swart JF, Vastert SJ, Marshall DA Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. *Patient* (2022). <https://doi.org/10.1007/s40271-022-00575-x>

This study highlights factors that affect pediatric rheumatologists' approaches to treatment decision making for biologics in patients with JIA. Such as the decisions to initiate and taper biologics. While also adding to the limited literature on approaches to treatment decision making.

## eHealth Updates

Over the last quarter, the eHealth platform has had a number of new updates, mainly:

- **Release of Version 11.1:** release notes have been sent to site coordinators that overview all changes.
- **SUCCEED-kids:** we are happy to announce that SUCCEED will also be supported on the eHealth platform!
- **Design and Wireframing:** Two milestones have been completed, *Decision Aids and Genomics Education*. With the PIs overlooking the content creation for these features, the initial implementation of these will soon be deployed to the platform.

## Questions?

🇨🇦 **Canadian** Sites please contact:

**Andrea Linares**  
Canadian Coordinator  
[Andrea.linares@ucalgary.ca](mailto:Andrea.linares@ucalgary.ca)

🇨🇦 **Study** Questions please contact:

**Patricia Cui**  
Project Manager  
[Patricia.cui@sickkids.ca](mailto:Patricia.cui@sickkids.ca)

🇳🇱 **Dutch** Sites please contact:

**Regina de Geus**  
Dutch Coordinator  
[R.deGeus@umcutrecht.nl](mailto:R.deGeus@umcutrecht.nl)

**Thank you to our funders and supporters:**

